Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Menkes disease (Menkes syndrome): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Menkes disease: the short answer

For Menkes disease, the US FDA has approved one medicine covered on this page, for a specific group of patients: Zycubo. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Zycubo.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is Menkes disease?

Menkes disease affects copper levels in the body. It is marked by sparse, kinky hair, failure to gain weight and grow as expected, and deterioration of the nervous system. Other signs include weak muscle tone, seizures and developmental delay. Symptoms usually begin in infancy, and affected children often do not live past age 3. Early treatment with copper may improve the outlook for some children.^[1]

It is caused by changes in the ATP7A gene and is inherited in an X-linked recessive pattern, so it mostly affects boys. The incidence of Menkes syndrome and its milder form, occipital horn syndrome, is estimated at 1 in 100,000 newborns.^[1]

Menkes disease in the Gulf

We did not find published Gulf-specific figures for Menkes disease that we could verify, so we do not give any. Because early copper treatment matters, families who suspect Menkes disease should ask a pediatric neurologist or metabolic specialist about testing without delay.^[1]

Zycubo is a US-approved copper replacement for Menkes disease. On 17 October 2026 it was not found in the SFDA drugs list or the Abu Dhabi Department of Health drug code list, so in most Gulf countries it would need a named-patient import request by the treating hospital.^{[2, 3, 4]}

US FDA-approved medicines for Menkes disease

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

Zycubo (copper histidinate)
FDA-approved for Menkes disease in children. It is a copper replacement given by injection under the skin. The label says it is not for occipital horn syndrome.^{[2, 5]}
US FDA approval: 12 January 2026. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.^{[3, 4]}
Country guides: Lebanon, Turkey, India

How families in the Gulf can access these medicines

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for Menkes disease

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for Menkes disease?

Yes. The medicine on this page has US FDA approval for a specific group of patients: Zycubo. The exact conditions are in the US label and are summarized above. Your specialist decides whether it fits.

Is Zycubo available in Saudi Arabia or the UAE?

Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Zycubo?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Is Zycubo used for occipital horn syndrome?

No. The US label says Zycubo is not indicated for occipital horn syndrome. It is approved for Menkes disease in children.

Sources for the last answer: ^[5]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.